Humanized Antibodies to the Extracellular Domains of Human N-Cadherin
- 技术优势
- Reduced immunogenicity Interacts with the human immune system Reduces tumor volume by ~29% in mice
- 技术应用
- Prostate cancer therapy Prostate cancer diagnosis
- 详细技术说明
- UCLA researchers have developed an antibody therapy for invasive prostate and bladder cancers that express N-cadherin. These antibodies are humanized, or modified to more closely resemble antibody variants produced naturally in humans. This humanization technique reduces the immunogenicity of antibodies and enables their interaction with the human immune system. The antibodies show increased binding to N-cadherin and therefore reduce the tumor volume in mice by ~29% in comparison to control mice. This antibody therapy can be used alone, as an antibody-drug conjugate, in radioimmunotherapy or in various combinatorial therapies with small molecule inhibitors or chemotherapy. This invention provides a therapy with increased specificity for prostate and bladder cancer patients that express the protein N-cadherin.
- *Abstract
-
UCLA researchers in the Department of Molecular and Medical Pharmacology have developed humanized antibody therapies for invasive prostate and bladder cancers that express N-cadherin.
- *Principal Investigation
-
Name: Robert Reiter
Department:
Name: Anna Wu
Department:
Name: Kirstin Zettlitz
Department:
- 其他
-
Background
Prostate cancer is the second leading cause of cancer death among men in the United States (National Cancer Institute). Unfortunately, systemic therapies such as chemotherapy suffer from low treatment efficacy. Antibodies can be used to increase treatment efficacy by binding to proteins expressed on the surface of cancerous cells. N-cadherin expression on cancerous prostate cells leads to treatment resistance towards targeted therapies and results in the rise of cancerous cells. Consequently, N-cadherin is an attractive target for diagnosis, therapy, and monitoring of disease progression. There is a need for antibody therapies that bind to N-cadherin in prostate and bladder cancers.
Related Materials
Additional Technologies by these Inventors
- System to Produce Biotinylated Proteins
- A Novel Immuno-PET Tracer for Imaging of CD20
- Fully Human Antibodies and Fragments Recognizing c-Met
Tech ID/UC Case
29540/2017-645-0
Related Cases
2017-645-0
- 国家/地区
- 美国
